Insoluble α-synuclein in alzheimer's disease without lewy body formation

Neurotoxicity Research

Volumn 7, Issue 1-2, 2005, Pages 69-76

  Broe, Melissa ^a   Shepherd, Claire E ^a   Mann, David M A ^b   Milward, Elizabeth A ^a   Gai, Wei Ping ^c   Thiel, Emma ^a   Halliday, Glenda M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Synuclein; Alzheimer's disease; Protein solubility; Senileplaques

Indexed keywords

ALPHA SYNUCLEIN; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

AGED; ALZHEIMER DISEASE; ANIMAL; ARTICLE; BIOSYNTHESIS; BRAIN; COMPARATIVE STUDY; FEMALE; HUMAN; LEWY BODY; MALE; METABOLISM; PATHOLOGY; SOLUBILITY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; BRAIN; FEMALE; HUMANS; LEWY BODIES; MALE; NERVE TISSUE PROTEINS; SOLUBILITY; SYNUCLEINS;

EID: 15844421282     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033777     Document Type: Article

References (41)

1. Arai Y, M Yamazaki, O Mori, H Muramatsu, G Asano and Y Katayama (2001) β-Synuclein-positive structures in cases with sporadic Alzheimer's disease: Morphology and its relationship to tau aggregation. Brain Res. 888, 287-296.
2. Arima K, T Mizutani, MA Alim, H Tonozuka-Uehara, Y Izumiyama, S Hirai and K Ueda (2000) NACP/α-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol. 100, 115-121.
3. Baba M, S Nakajo, PH Tu, T Tomita, K Nakaya, VMY Lee, JQ Trojanowski and T Iwatsubo (1998) Aggregation of α synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
4. Bajo M, BC Yoo, N Cairns, M Gratzer and G Lubec (2001) Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21, 293-301.
5. Bayer TA, P Jakala, T Hartmann, L Havas, C McLean, JG Culvenor, QX Li, CL Masters, P Falkai and K Beyreuther (1999) α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores. Neurosci. Lett. 266, 213-216.
6. Campbell BCV, Q-X Li, JG Culvenor, P Jäkälä, R Cappai, K Beyreuther, CL Masters and CA McLean (2000) Accumulation of insoluble α-synuclein in dementia with Lewy bodies. Neurobiol. Dis. 7, 192-200.
7. Culvenor JG, CA McLean, S Cutt, BCV Campbell, F Maher, P Jäkälä, T Hartmann, K Beyreuther, CL Masters and Q-X Li (1999) Non-β component of Alzheimer's disease amyloid (NAC) revisited. NAC and α-synuclein are not associated with Aβ amyloid. Am. J. Pathol. 155, 1173-1181.
8. Ditaranto K, TL Tekirian and A J Yang (2001) Lysosomal membrane damage in soluble β-mediated cell death in Alzheimer's disease. Neurobiol. Dis. 8, 19-31.
9. El-Agnaf OMA and GB Irvine (2000) Review: Formation and properties of amyloid-like fibrils derived from ?-synuclein and related proteins. J. Struct. Biol. 130, 300-309.
10. Goedert M (2001) α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501.
11. Iwai A, E Masliah, MP Sundsmo, R DeTeresa, M Mallory, DP Salmon and T Saitoh (1996) The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Brain Res. 720, 230-234.
12. Lee H-J, F Khoshaghideh, S Patel and S-J Lee (2004) Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24, 1888-1896.
13. Lee HJ, C Choi and SJ Lee (2002) Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678.
14. Lippa CF, H Fujiwara, DMA Mann, B Gaisson, M Baba, ML Schmidt, LE Nee, B O'Connell, DA Pollen, P St George-Hyslop, B Ghetti, D Nochlin, TD Bird, NJ Cairns, VMY Lee, T Iwatsubo and JQ Trojanowski (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
15. Marui W, E Iseki, K Ueda and K Kosaka (2000) Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. J. Neurol. Sci. 174, 81-84.
16. Masliah E, A Iwai, M Mallory, K Uéda and T Saitoh (1996) Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 148, 201-210.
17. Masliah E, E Rockenstein, I Veinbergs, Y Sagara, M Mallory, M Hashimoto and L Mucke (2001) β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 12245-12250.
18. Michikawa M, J-S Gong, Q-W Fan, N Sawamura and K Yanagisawa (2001) A novel action of Alzheimer's amyloid β-protein (Aβ): Oligomeric Aβ promotes lipid release. J. Neurosci. 15, 7226-7235.
19. Mori T, D Paris, T Town, AM Rojiani, DL Sparks, A Delledonne, F Crawford, LI Abdullah, JA Humphrey, DW Dickson and MJ Mullan (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APPsw mice. J. Neuropathol. Exp. Neurol. 60, 778-785.
20. Mukaetova-Ladinska EB, F Garcia-Siera, J Hurt, HJ Gertz, J Xuereb, R Hills, C Brayne, FA Huppert, ES Paykel, M McGee, R Jakes, WG Honer, CR Harrington and CM Wischik (2000a) Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am. J. Pathol. 157, 623-636.
21. Mukaetova-Ladinska EB, J Hurt, R Jakes, J Xuereb, WG Honer and CM Wischik (2000b) α-Synuclein inclusions in Alzheimer and Lewy body diseases. J. Neuropathol. Exp. Neurol. 59, 408-417.
22. Paik S, J-H Lee, D-H Kim, C-S Chang and Y-S Kim (1998) Selfoligomerization of NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal Aβ fragment (residues 25-35). FEBS Lett. 421, 73-76.
23. Perrin RJ, WS Woods, DF Clayton and JM George (2001) Exposure to long chain polysaturated fatty acids trigger rapid multimerization of synucleins. J. Biol. Chem. 276, 41958-41962.
24. Refolo LM, MA Pappolla, J LaFrancois, B Malester, SD Schmidt, T Thomas-Bryant, GS Tint, R Wang, M Mercken, SS Petanceska and KE Duff (2001) A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899.
25. Rekas A, CG Adda, JA Aquilina, KJ Barnham, M Sunde, D Galatis, NA Williamson, CL Masters, RF Anders, CV Robinson, R Cappai and JA Carver (2004) Interaction of the molecular chaperone αB-crystallin with α-synuclein: Effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 340, 1167-1183.
26. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
27. Sharon R, I Bar-Josef, MP Frosch, DM Walsh, JA Hamilton and DJ Selkoe (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595.
28. Sharon R, MS Goldberg, I Bar-Josef, RA Betensky, J Shen and DJ Selkoe (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA 98, 9110-9115.
29. Sparks DL (1996) Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol. Aging 17, 291-299.
30. Sparks DL, SW Scheff, JC Hunsaker, H Liu, T Landers and DR Gross (1994) Inducation of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94.
31. Stirling JW and PS Graff (1995) Antigen unmasking for immunoelectron microscopy: Labeling is improved by treating with sodium ethoxide or sodium metaperiodate, then heating on retrieval medium. J. Histochem. Cytochem. 43, 115-123.
32. Takeda A, M Hashimoto, M Mallory, M Sundsumo, L Hansen and E Masliah (2000) C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol. 99, 296-304.
33. Takeda A, M Mallory, M Sundsmo, W Honer, L Hansen and E Masliah (1998) Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367-372.
34. Terai K, A Iwai, S Kawabata, Y Tasaki, T Watanabe, K Miyata and T Yamaguchi (2001) β-Amyloid deposits in transgenic mice expressing human β-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 104, 299-310.
35. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18 Suppl. 4, S1-S2.
36. Ueda K, H Fukushima, E Maslaih, Y Xia, A Iwai, M Yoshimoto, DAC Otero, J Kondo, Y Ihara and T Saitoh (1993) Molecular cloning of cDNA encoding an unrecognised component of amyloid in Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA 90, 11282-11286.
37. Uversky VN, EM Cooper, KS Bower, J Li and AL Fink (2002a) Accelerated α-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99-103.
38. Uversky VN, J Li, P Souillac, IS Millett, S Doniach, R Jakes, M Goedert and AL Fink (2002b) Biophysical properties of the synucleins and their propensities to fibrillate: Inhibition of α-synuclein assembly by β- and γ-synucleins. J. Biol. Chem. 277, 11970-11978.
39. Wirths O, S Weickert, K Majtenyi, L Havas, PJ Kahle, M Okochi, C Haass, G Multhaup, K Beyreuther and TA Bayer (2000) Lewy body variant of Alzheimer's disease: α-synuclein in dystrophic neurites of Aβ plaques. Neuroreport 11, 3737-3741.
40. Yang AJ, D Chandswangbhuvana, L Margol and CG Glabe (1998) Loss of endosomal/lysosomal membrane permeability is an early event in amyloid Aβ1-42 pathogenesis. J. Neurosci. Res. 52, 691-698.
41. Yip CM, EA Elton, AA Darabie, MR Morrison and J McLaurin (2001) Cholesterol, a modulator of membrane-associated Aβ fibrillogenesis and neurotoxicity. J. Mol. Biol. 311, 723-734.